Crescent Biopharma Statistics
Total Valuation
CBIO has a market cap or net worth of $490.13 million. The enterprise value is $302.51 million.
| Market Cap | 490.13M |
| Enterprise Value | 302.51M |
Important Dates
The next estimated earnings date is Wednesday, July 29, 2026, before market open.
| Earnings Date | Jul 29, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
CBIO has 33.23 million shares outstanding.
| Current Share Class | 27.57M |
| Shares Outstanding | 33.23M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +44.35% |
| Owned by Insiders (%) | 6.17% |
| Owned by Institutions (%) | 50.52% |
| Float | 14.10M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 41.25 |
| Forward PS | 457.46 |
| PB Ratio | 2.73 |
| P/TBV Ratio | 2.73 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 25.46 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 13.78, with a Debt / Equity ratio of 0.01.
| Current Ratio | 13.78 |
| Quick Ratio | 13.33 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -152.04 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | -88.21% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | $216,055 |
| Profits Per Employee | -$2.95M |
| Employee Count | 55 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, CBIO has paid $2.00 million in taxes.
| Income Tax | 2.00M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +12.25% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +12.25% |
| 50-Day Moving Average | 18.09 |
| 200-Day Moving Average | 14.67 |
| Relative Strength Index (RSI) | 33.09 |
| Average Volume (20 Days) | 493,850 |
Short Selling Information
The latest short interest is 3.67 million, so 11.05% of the outstanding shares have been sold short.
| Short Interest | 3.67M |
| Short Previous Month | 3.35M |
| Short % of Shares Out | 11.05% |
| Short % of Float | 26.05% |
| Short Ratio (days to cover) | 10.07 |
Income Statement
In the last 12 months, CBIO had revenue of $11.88 million and -$162.08 million in losses. Loss per share was -$8.05.
| Revenue | 11.88M |
| Gross Profit | 11.88M |
| Operating Income | -163.14M |
| Pretax Income | -160.08M |
| Net Income | -162.08M |
| EBITDA | n/a |
| EBIT | -163.14M |
| Loss Per Share | -$8.05 |
Balance Sheet
The company has $189.16 million in cash and $1.54 million in debt, with a net cash position of $187.62 million or $5.65 per share.
| Cash & Cash Equivalents | 189.16M |
| Total Debt | 1.54M |
| Net Cash | 187.62M |
| Net Cash Per Share | $5.65 |
| Equity (Book Value) | 183.85M |
| Book Value Per Share | 5.41 |
| Working Capital | 181.37M |
Cash Flow
In the last 12 months, operating cash flow was -$69.62 million and capital expenditures -$1.07 million, giving a free cash flow of -$70.68 million.
| Operating Cash Flow | -69.62M |
| Capital Expenditures | -1.07M |
| Depreciation & Amortization | 148,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -70.68M |
| FCF Per Share | -$2.13 |
Margins
| Gross Margin | 100.00% |
| Operating Margin | -1,372.86% |
| Pretax Margin | -1,347.11% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CBIO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -33.07% |
| FCF Yield | -14.42% |
Analyst Forecast
The average price target for CBIO is $31.00, which is 110.17% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $31.00 |
| Price Target Difference | 110.17% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 8 |
| Revenue Growth Forecast (3Y) | -8.90% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
CBIO has an Altman Z-Score of 7.59 and a Piotroski F-Score of 1.
| Altman Z-Score | 7.59 |
| Piotroski F-Score | 1 |